2023 WHO think tank on treatment optimization of HIV

Overview

This report reviews key clinical trials, observational studies, and programmatic data on newer antiretrovirals to inform future updates to global HIV treatment policies. The report also reviewed the latest data on the safety and efficacy of dolutegravir, tenofovir alafenamide, and long-acting ARV-containing regimens in people living with HIV, including pregnant women. Critical gaps in clinical knowledge, research, monitoring, and surveillance on the transition to these new antiretrovirals were discussed, and future research priorities were summarized. 

The primary audience for this report includes national HIV program managers, clinicians, and healthcare providers. This document will also be of interest to treatment advisory boards, international agencies and organizations that provide technical and financial support to HIV programmes.